CHICAGO, May 28, 2013 /PRNewswire/ -- Clearbridge BioMedics today revealed its next generation ClearCell® FX System, which is developed for in vitro diagnostic applications. This will be on showcase at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting at booth number 23092, from 31 May to 4 June 2013.
The new ClearCell® FX System is based on inertial focusing microfluidics and is label-free. Circulating Tumor Cells (CTCs) in a patient's blood sample are separated and isolated using this novel inertial focusing spiral microfluidics in the single-use CTChip® FR. The larger and denser CTCs are separated from the other blood cells within the spiral biochip due to biomechanical differences and are subsequently focused into an enriched CTC "stream". These cell "streams" are then channelled and collected in a tube and can be readily used for downstream molecular analysis, such as mutation testing for targeted therapies. These retreived cancer cells remain wholly intact and viable due to the label-free separation process used. The ClearCell® FX System will allow physicians and researchers to rapidly isolate CTCs for further diagnostic testing and even cell culture, paving the way for the use of CTCs in treatment monitoring and personalized medicine.
"The technology for the ClearCell® FX system was developed by Clearbridge BioMedics in collaboration with the National University of Singapore and the Singapore-MIT Alliance for Research and Technology (SMART) center. Our new system will subsequently be undergoing regulatory approval in the U.S. and Europe. Once approved, it will be one of the world's first label-free CTC enrichment systems for diagnostic use. Clearbridge BioMedics believes this system will be an ideal companion diagnostic system that complements various cancer therapies," said Mr
|SOURCE Clearbridge BioMedics|
Copyright©2012 PR Newswire.
All rights reserved